10-K: ChromaDex Reports Profitable 2024, Driven by Strong Growth in Consumer Products and Ingredients Segments

ChromaDex Corporation reports a profitable 2024, driven by a 19% increase in net sales, primarily from its Consumer Products and Ingredients segments.

Summary

• ChromaDex Corporation, a global bioscience company focused on healthy aging, reported a net income of $8.6 million for the year ended December 31, 2024, compared to a net loss of $4.9 million in the previous year.
• Net sales increased by 19% to $99.6 million in 2024, up from $83.6 million in 2023.
• The Consumer Products segment saw a 10% increase in sales, reaching $76.8 million, driven by e-commerce growth and higher sales to distributor partners.
• The Ingredients segment experienced a significant 78% surge in sales, totaling $19.8 million, primarily due to new partnerships and the launch of pharmaceutical-grade Niagen.
• The Analytical Reference Standards and Services segment reported a slight increase in sales to $3.0 million.
• Gross profit increased by 21% to $61.6 million, with a gross margin of 61.8%.
• Sales and marketing expenses increased by 11% to $29.5 million, while research and development expenses rose by 21% to $6.0 million.
• General and administrative expenses decreased by 26% to $18.4 million, primarily due to reduced royalty expenses and credit loss expenses.
• The company had cash and cash equivalents of $44.7 million as of December 31, 2024.
• ChromaDex is committed to purchasing approximately $4.8 million of total inventory between January 1, 2025 and March 31, 2025, per the Tenth Amendment to the Manufacturing and Supply Agreement with W.R. Grace & Co.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, particularly the return to profitability and significant revenue growth. However, there are some risks and uncertainties that temper the overall sentiment.

Positives

• Significant increase in net sales, indicating strong market demand for ChromaDex's products.
• Return to profitability, demonstrating improved financial performance and operational efficiency.
• Strong growth in the Ingredients segment, highlighting the success of new partnerships and product launches.
• Reversal of accrued royalties, positively impacting general and administrative expenses.
• Successful settlement in the California Action with Elysium, resulting in a financial benefit for ChromaDex.

Negatives

• Reliance on a single supplier, W.R. Grace, for NRC, posing a potential risk to the supply chain.
• Ongoing legal proceedings with Elysium in Delaware, potentially resulting in significant financial liabilities.
• Purchase obligations of approximately $11.2 million related to inventory purchase commitments.

Risks

• The company's future performance depends on sales of its Tru Niagen product.
• The company relies on a single supplier, W.R. Grace, for NRC and a limited number of third-party suppliers for the raw materials required to produce its products.
• The company may become subject to claims of infringement or misappropriation of the intellectual property rights of others.
• The company is subject to regulation by various federal, state and foreign agencies that require it to comply with a wide variety of regulations.
• The company may become involved in securities class action litigation that could divert management's attention and harm its business.
• The company has a limited operating history in China and its ability to develop successful channels in China is subject to legal, political, economic and social uncertainties.
• The company is subject to financial and operating covenants in its business financing agreement with Western Alliance Bank, as amended (Credit Agreement) and any failure to comply with such covenants, or obtain waivers in the event of non-compliance, could limit its borrowing availability under the Credit Agreement, resulting in its being unable to borrow under the Credit Agreement and materially adversely impact its liquidity.

Future Outlook

The company anticipates that its current unrestricted cash and cash equivalents and cash to be generated from net sales will be sufficient to meet its financial obligations as they become due over at least the next twelve months and beyond. However, the company may seek additional funds to support both its short-term and long-term operating objectives, either through additional equity or debt financings or collaborative agreements or from other sources.

Industry Context

The health and wellness, anti-aging, and dietary supplement industries are highly competitive, with ChromaDex facing competition from companies with greater financial and human resources, as well as those selling inaccurately or falsely labeled products.

Comparison to Industry Standards

• The global wellness industry market was approximately $6.3 trillion in 2023, nearly 17% higher than its size in 2021, according to data from Global Wellness Institute.
• The Global Wellness Institute projects the overall wellness economy to grow approximately 7.3% annually, or 42% in total, from 2023 to 2028.
• The global dietary supplements market size was estimated at $178 billion in 2023, and is expected to grow at a compound annual growth rate of 9.1% from 2024 to 2030, according to data from Grand View Research.
• The intravenous hydration therapy market size was estimated at $2 billion in 2022, and is expected to grow at a compound annual growth rate of 8.0% from 2023 to 2030, according to data from Grand View Research.

Management Changes

Legal Proceedings

• The company is involved in ongoing legal proceedings with Elysium Health, LLC in Delaware, related to patent infringement.
• The company secured a settlement agreement in the California Action with Elysium, resulting in a $2.65 million payment to ChromaDex.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance and return to profitability.
• Employees: Potential for increased job security and opportunities due to company growth.
• Customers: Continued access to high-quality products and services.
• Suppliers: Potential for increased business opportunities due to company growth.

Next Steps

• The company will continue to monitor the creditworthiness and payment behavior of its major customers.
• The company will continue to pursue new partnerships and business opportunities which helps to diversify its customer base and minimize the risk of an overreliance on any particular trade receivable.
• The company will continue to analyze the potential impact of any additional transactions undertaken upon the utilization of the net operating losses on a go forward basis.

Key Dates